Skip to main content

Table 1 Frequency distribution of established and putative risk factors for prostate cancer among cases and controls

From: Human kallikrein-2 gene and protein expression predicts prostate cancer at repeat biopsy

Subgroup   Cases (n = 180), (%) Controls (n = 761), (%) P (χ 2 )*
Age <50 4 (14.3) 24 (85.7) 0.19
50-60 41 (15.4) 225 (84.6)
60-70 87 (20.0) 348 (80.4)
>70 48 (22.6) 164 (77.4)
PSA (ng/mL) <10.0 120 (18.6) 527 (81.4) 0.65
10.0-20.0 46 (19.7) 188 (80.3)
>20.0 14 (23.3) 46 (76.7)
TRUS volume (cc) <47.0 77 (28.5) 193 (71.5) <0.0001
47.0-67.0 51 (21.0) 192 (79.0)
67.0-93.1 27 ( 12.7) 185 (87.3)
>93.1 25 (11.6) 191 (88.4)
Family history Negative 152 (18.5) 668 (81.5) 0.23
Positive 28 (23.1) 93 (76.9)
Presence of LUTS Negative 104 (21.4) 382 (78.6) 0.067
Positive 76 (16.7) 379 (83.3)
DRE Normal 130 (18.6) 569 (81.4) 0.61
Abnormal 48 (20.1) 191 (79.9)
Ethnic background Other 3 (9.1) 30 (90.9) 0.074
Asian 8 (11.9) 59 (88.1)
White 147 (19.4) 609 (80.6)
Black 22 (25.9) 63 (74.1)
Initial Biopsy Pathology Normal or BPH 93 (14.8) 537 (85.2) < 0.0001
HGPIN 62 (25.6) 180 (74.4)
ASAP 25 (36.2) 44 (63.8)
rs2664155 (KL1) GG 80 (18.4) 354 (81.6) 0.35
GA 74 (18.5) 326 (81.5)
AA 26 (24.3) 81 (75.7)
rs198977 (KL2) CC 70 (15.8) 374 (84.2) 0.018
CT 82 (20.9) 311 (79.1)
TT 28 (26.9) 76 (73.1)
Mean (Median) hK2 Level (ng/mL)   0. 246 (0.193) 0.228 (0.163) 0.02
  1. Abbreviations: TRUS = Transrectal Ultrasound, DRE = Digital Rectal Exam, LUTS = Lower Urinary Tract Symptoms; *Chi-Square Test.